
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.15 | -7.77202072539 | 1.93 | 2.0299 | 1.77 | 1188442 | 1.92210628 | CS |
4 | -0.28 | -13.5922330097 | 2.06 | 2.23 | 1.58 | 2272878 | 1.84593669 | CS |
12 | -0.24 | -11.8811881188 | 2.02 | 3.08 | 1.2905 | 2480852 | 2.23211771 | CS |
26 | -2.39 | -57.3141486811 | 4.17 | 4.59 | 1.2905 | 1513392 | 2.34540296 | CS |
52 | -3.63 | -67.0979667283 | 5.41 | 13.07 | 1.2905 | 1167080 | 4.06664587 | CS |
156 | -10.63 | -85.6567284448 | 12.41 | 43.69 | 1.2905 | 874720 | 11.30043003 | CS |
260 | -18.22 | -91.1 | 20 | 43.69 | 1.2905 | 663289 | 11.24212586 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.